GMS+ implantation not effective for IOP control

Article

Gold Micro Shunt Plus (GMS+) implantation is not an effective method for controlling IOP in glaucoma patients, according to a recent study in the journal BMC Ophthalmology.

Gold Micro Shunt Plus (GMS+) implantation is not an effective method for controlling IOP in glaucoma patients, according to a recent study in the journal BMC Ophthalmology.

Dr Arno Hueber et al., Department of Ophthalmology, University of Cologne, Germany, conducted a retrospective study on 31 eyes of 31 patients with severe glaucoma and uncontrolled IOP. Each patient underwent GMS+ implantation by means of a full-thickness scleral flap. The main outcome measures were surgical failure or success, determined by intraocular pressure and adverse effects.

Of the eyes included in the study, 30 met one of the failure criteria. Additional surgery was performed due to elevated IOP in 24 eyes and adverse effects in 2 eyes.

The remaining four eyes presented with an IOP reduction of less than 20% with comparable medication. The team explanted six GMS+’s because of IOP elevation in 2 eyes, rubeosis in 2 eyes and low-grade inflammation in 2 eyes.

GMS+ implantation is not effective for the control of IOP in glaucoma patients and the reason for the appearance of low grade inflammation and rubeosis iridis in 4 eyes remains unknown.

To read the abstract please click here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.